Steven M. Chan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Steven M. Chan has a total of 287 co-authors. Here are the top co-authors by number of shared publications:
- Mark David Minden
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
63 shared publications - Yitong Yang
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
55 shared publications - Mohsen Hosseini
Princess Margaret Cancer Centre, Toronto, ON, Canada
42 shared publications - Severine Cathelin
Princess Margaret Cancer Centre, University Health Network, Toronto, Canada
41 shared publications - Yu-Chuan Liu
Princess Margaret Cancer Centre , Toronto, Ontario, M5G 1L7
40 shared publications - Anne Tierens
21Laboratory Medicine Program, University Health Network and University of Toronto, Toronto, Canada
39 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
LY3410738 selectivity and off-target profiling in Eurofins DiscoverX and Eurofins Discovery (CEREP) assays
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
LY3410738 selectivity and off-target profiling in Eurofins DiscoverX and Eurofins Discovery (CEREP) assays
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Animal body weight during LY3410738 dosing in different AML PDX models.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Animal body weight during LY3410738 dosing in different AML PDX models.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
LY3410738 exhibited potent inhibition of 2-HG levels in MOLM-14 AML cell line
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
LY3410738 exhibited potent inhibition of 2-HG levels in MOLM-14 AML cell line
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Efficacy of LY3410738 monotherapy in mutant IDH1R132H AML PDX models (hCD45+ confirmation of AML clearance).
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Efficacy of LY3410738 monotherapy in mutant IDH1R132H AML PDX models (hCD45+ confirmation of AML clearance).
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Efficacy of LY3410738 alone or in combination with standard-of-care treatment in mutant IDH2R140Q AML PDX model
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Efficacy of LY3410738 alone or in combination with standard-of-care treatment in mutant IDH2R140Q AML PDX model
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
LY3410738 is a dual inhibitor of mutant IDH1/2 and maintains activity against 2HG-restoring mutations.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
LY3410738 is a dual inhibitor of mutant IDH1/2 and maintains activity against 2HG-restoring mutations.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Example dot plots and gating scheme for flow cytometry analysis.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Example dot plots and gating scheme for flow cytometry analysis.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Efficacy of LY3410738 in combination with midostaurin in mIDH1R132H, FLT3-ITD, DNMT3A, ZRSR2 AML PDX model.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Efficacy of LY3410738 in combination with midostaurin in mIDH1R132H, FLT3-ITD, DNMT3A, ZRSR2 AML PDX model.
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
In vitro dose-dependent inhibition of 2-HG production and H3K9me2 hypermethylation
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
In vitro dose-dependent inhibition of 2-HG production and H3K9me2 hypermethylation
- Open Access
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Additional supplementary methods.
- 3 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models
Additional supplementary methods.